SPRB vs SVRA
SPRB: Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo Syndrome Type B. SVRA: Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
Side-by-side fundamentals
| Metric | SPRB | SVRA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $44.60 | $5.65 | |
| Market cap as of 2026-07-23 | $123M | $1.2B | |
| PEG as of 2026-07-23 | n/a | -0.81 | |
| Net margin as of 2026-07-23 | -1079.9% | -4253.9% | SPRB higher |
| Gross margin as of 2026-07-23 | n/a | +100.0% | |
| Operating margin as of 2026-07-23 | -1143.4% | -4150.0% | SPRB higher |
| ROE as of 2026-07-23 | -155.4% | -87.2% | SVRA higher |
| ROA as of 2026-07-23 | -101.7% | -66.4% | SVRA higher |
| Debt / equity as of 2026-07-23 | 0.19 | 0.17 | SVRA lower |
| Beta as of 2026-07-23 | 3.45 | 0.25 | |
| 1-year return as of 2026-07-22 close | +423.9% | +134.4% | SPRB higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.